| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $63.7M | +9.0% |
| Cost of Revenue | $5.6M | +6.5% |
| R&D Expense | $127.6M | +109.0% |
| SG&A Expense | $60.7M | +78.7% |
| Operating Income | -$171.8M | -108.5% |
| Income Tax | $0 | — |
| Net Income | -$193.5M | -139.7% |
| EPS (Basic) | -$1.22 | -20.8% |
| EPS (Diluted) | -$1.22 |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $392.1M | +100.2% |
| Accounts Receivable | $32.4M | +23.7% |
| Inventory | $3.0M | +31.9% |
| Current Assets | $441.0M | +89.9% |
| Total Assets | $457.9M | +81.7% |
| Current Liabilities | $41.4M | +18.5% |
| Total Liabilities | $142.6M | -11.4% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$134.7M | -91.8% |
| Capital Expenditures | $1.3M | -78.8% |
| Investing Cash Flow | -$1.3M | +78.8% |
| Financing Cash Flow | $332.1M | +95.6% |
| Free Cash Flow | -$136.0M | -78.1% |
| -19.6% |
| Stockholders' Equity |
| $315.3M |
| +246.0% |